Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening

INTRODUCTION: Hemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal immunoglobulin for intravenous administration [i.e., intravenous immunoglobulin (IVIG)]. Anti-A/B isoagglutinins (also referred to as isohemagglutinins) originating from d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Ther
Autors principals: Siani, Brigitte, Willimann, Katharina, Wymann, Sandra, Marques, Adriano A., Widmer, Eleonora
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4254866/
https://ncbi.nlm.nih.gov/pubmed/24841428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13554-014-0016-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars